Evidence map›Paper›PMID 40457602›Full record

Observational studyRenal failure2025

The long-term impact of mild COVID-19 on cardiovascular disease and mortality in patients on hemodialysis: a post-Omicron era retrospective observational study.

Akiko Okamoto, Teppei Okamoto, Takaki Ichiyama, Takafumi Fukushima, Sosuke Omizo, Himawari Asanuma, Hiroyuki Sato, Hisashi Sakurai, Anna Yoneyama, Fumiya Yoneyama and 14 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Akiko OkamotoDepartment of Urology, Oyokyo Kidney Research Institute Hirosaki Hospital, Hirosaki, Japan.
Teppei OkamotoDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.ORCID 0000-0002-3750-3811
Takaki IchiyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Takafumi FukushimaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Sosuke OmizoDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Himawari AsanumaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hiroyuki SatoDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hisashi SakuraiDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Anna YoneyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Fumiya YoneyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Noritaka IshiiDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Takuya OishiDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Ryuma TanakaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hikari MiuraDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Tomoko HamayaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hirotake KodamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Naoki FujitaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hiromi MurasawaDepartment of Urology, Oyokyo Kidney Research Institute Hirosaki Hospital, Hirosaki, Japan.
Hayato YamamotoDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Atsushi ImaiDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Hisao SaitohDepartment of Urology, Oyokyo Kidney Research Institute Hirosaki Hospital, Hirosaki, Japan.
Shingo HatakeyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Chikara OhyamaDepartment of Urology, Hirosaki University School of Medicine, Hirosaki, Japan.
Tadashi SuzukiDepartment of Urology, Oyokyo Kidney Research Institute Hirosaki Hospital, Hirosaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe long-term cardiovascular (CVD) and mortality risk associated with mild COVID-19 infections in patients on hemodialysis (HD) during the post-Omicron era remains unclear. This study evaluates clinical outcomes in patients on HD following Omicron infection.

methodsThis retrospective observational study included 462 patients from a single center. All mild COVID-19 cases occurred after January 2022. The first analysis compared patients with prior mild COVID-19 (COVID-19 history [+],

resultsAfter 761 days, 100 CVD events including 51 cardiovascular deaths and 58 non-CVD deaths occurred. The CVD risk did not significantly differ between the COVID-19 history (+) and infection (-) groups (Hazard ration [HR]: 0.50, 95% confidence interval [CI]: 0.25-1.01,

conclusionMild COVID-19 infections does not significantly increase long-term CVD and mortality risk in patients on HD in the post-Omicron era.

Indexed as

Cardiovascular DiseasesCOVID-19Kidney Failure, ChronicRenal DialysisAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2cardiovascular diseaseCOVID-19hemodialysismild infectionOmicron variant

Identifiers

PMID40457602
PMCPMC12135085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.